BARDA facility

News report highlights CRB client in the race for a virus vaccine

Jul 10, 2020

With COVID-19 cases persisting, and even surging in some parts of the world, the race to identify and mass-produce a safe and effective vaccine carries new urgency. Emergent BioSolutions, a leading biopharmaceutical company with deep experience in outbreak defense, is gaining attention for its large-scale vaccine production facility – designed and constructed by CRB – as it works alongside some of the world’s biggest pharmaceutical companies to ramp up production of a COVID-19 vaccine.

CBS News, in a recent segment exploring the mechanics of the global vaccine response, profiled Emergent BioSolutions’ Center for Innovation in Advanced Development and Manufacturing (CIADM) facility in Baltimore, Maryland. The CIADM facility is one of only three in the United States designed for rapid development and manufacturing capabilities to respond to an influenza pandemic–manufacturing 50 million doses of novel pandemic flu vaccine within four months of strain identification. The facility is designed to produce up to hundreds of millions of doses annually.

“Emergent BioSolutions is gearing up now,” the CBS report reads, “preparing 4,000-liter tanks, to have hundreds of millions of doses ready to go if and when any of its clients … make it to the finish line in the race to a vaccine.”

Using its ONEsolution™ integrated project delivery approach, CRB’s combined design, engineering and construction in a unified project team to provide flexibility, adapt quickly to changes in design and scope, and minimize project disruption. ONEsolution™, coupled with CRB’s process expertise and experience with the federal Biomedical Advanced Research and Development Authority (BARDA), helped Emergent BioSolutions efficiently complete a facility that is prepared for both the current threat and others on the horizon. The CIADM is highly adaptable to fluctuations in capacity demand that could arise from pandemics with the recent addition of the 4,000-liter bioreactors referenced in the CBS story.

You can learn more details about CRB’s work with Emergent BioSolutions here.

Visit our Insights page!

Related Content


COVID-19 drug development strategies

COVID-19 drug development strategies for the near-term, medium-term and long-term.

Read More

Keys to accelerating your COVID-19 drug campaign

At CRB, we have the experience, the tools, and the flexibility to help your facility respond to pandemic response production to reliable, commercial-scale capacity as fast as possible.

Read More